For Immediate Release
Joseph Fishkin, MD, LLC Now an Accredited Dry Eye Center
EMERSON, NEW JERSEY — March 1, 2013 — The office of Dr. Joseph Fishkin announced today that it has installed a TearLab® Osmolarity System and its staff has been fully trained on the use of this breakthrough technology. The center is the first in Northern New Jersey to be able to provide TearLab testing for Dry Eye Disease (“DED”).
DED is a common condition in which the eye does not produce enough tears to keep the surface of the eye sufficiently lubricated. It affects approximately 40 million people in the U.S. and 100 million people worldwide. In the U.S., less than 5% of the DED patient population has been diagnosed and is being treated, according to Healthcare Maintenance Organizations data. In its mild to moderate forms, it can impact vision and the ability to go about daily activities. In its more severe forms, DED can lead to permanent loss of vision.
The TearLab Osmolarity System uses a novel lab-on-a-chip approach to measure tear osmolarity and can produce a sample-to-answer result in less than 30 seconds. TearLab eliminates the challenges that previously prevented accurate point-of-care testing for osmolarity.
Dr. Joseph Fishkin, Comprehensive Ophthalmologist and an area leader in the field of Dry Eye management, said, “Today’s announcement further demonstrates our commitment to building a practice that is dedicated to providing the highest quality of care using advanced ophthalmic diagnostic techniques and treatments. Equipped with the TearLab Osomolarity System, we can now use quantitative data at the point of care to aid in the diagnosis of DED and to improve our ability to manage these patients.”
About Joseph Fishkin, MD LLC
Dr. Joseph Fishkin is a Board-Certified Comprehensive Ophthalmologist. He treats all ages, and specializes in all aspects of eye care, including cataract surgery, laser vision correction, contact lenses, glaucoma and eye infections. Over the past five years, he has continuously been awarded both the Patients' Choice award, and the Most Compassionate Doctor award, a distinction shared with fewer than 3% of the nation's doctors.
About TearLab Corporation
TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.
Joseph Fishkin, MD, LLC